B

BioMaxima SA
WSE:BMX

Watchlist Manager
BioMaxima SA
WSE:BMX
Watchlist
Price: 12.95 PLN 0.78%
Market Cap: zł54.3m

Operating Margin

2.4%
Current
Declining
by 1.8%
vs 3-y average of 4.2%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
2.4%
=
Operating Income
zł1.5m
/
Revenue
zł60.7m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
2.4%
=
Operating Income
zł1.5m
/
Revenue
zł60.7m

Peer Comparison

Country Company Market Cap Operating
Margin
PL
BioMaxima SA
WSE:BMX
54.3m PLN
Loading...
JP
Hoya Corp
TSE:7741
8.5T JPY
Loading...
CH
Alcon AG
SIX:ALC
32B CHF
Loading...
US
Medline Inc
NASDAQ:MDLN
37.3B USD
Loading...
DK
Coloplast A/S
CSE:COLO B
124.3B DKK
Loading...
US
Align Technology Inc
NASDAQ:ALGN
12.2B USD
Loading...
UK
ConvaTec Group PLC
LSE:CTEC
4.8B GBP
Loading...
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
44.5B CNY
Loading...
CA
Bausch + Lomb Corp
NYSE:BLCO
6.1B USD
Loading...
CH
Ypsomed Holding AG
SIX:YPSN
4.6B CHF
Loading...
US
Merit Medical Systems Inc
NASDAQ:MMSI
4.9B USD
Loading...

Market Distribution

In line with most companies in Poland
Percentile
40th
Based on 835 companies
40th percentile
2.4%
Low
-10 083 900% — -1.5%
Typical Range
-1.5% — 11.7%
High
11.7% — 195 905.3%
Distribution Statistics
Poland
Min -10 083 900%
30th Percentile -1.5%
Median 5.4%
70th Percentile 11.7%
Max 195 905.3%

BioMaxima SA
Glance View

Market Cap
54.3m PLN
Industry
Health Care

Biomaxima SA operates in the field of biotechnology and laboratory diagnostics. The company is headquartered in Lublin, Woj. Lubelskie. The company went IPO on 2010-06-08. The company manufactures and distributes reagents and equipment for the laboratory diagnosis. The company produces reagents for the in vitro diagnosis. The main product groups offered by BioMaxima include: diagnostic reagents and analyzers for clinical biochemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ion-selective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers; analyzers for gasometric tests and critical blood parameters tests. The firm supplies hospitals and laboratories in Poland, as well as in Lithuania, Latvia, Romania and France. On March 20, 2014, the Company merged with its wholly owned subsidiary Cebo Sp z o o.

BMX Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
2.4%
=
Operating Income
zł1.5m
/
Revenue
zł60.7m
What is BioMaxima SA's current Operating Margin?

The current Operating Margin for BioMaxima SA is 2.4%, which is below its 3-year median of 4.2%.

How has Operating Margin changed over time?

Over the last 3 years, BioMaxima SA’s Operating Margin has decreased from 24.7% to 2.4%. During this period, it reached a low of -0.6% on Jun 30, 2024 and a high of 24.7% on Sep 30, 2022.

Back to Top